June 22, 10:30 am PDT / 1:30 pm EDT

Several proposals to lower drug costs have been introduced in recent years in response to growing public concern about drug prices and affordability. A key element included in recent proposals would tie the prices of certain medicines to the prices paid in other countries. As discussions on these policies continue, it is important to consider how these proposals may affect research and development decisions and capital investments in the sector. In this session, experts will discuss how policymakers can address patients' concerns about drug prices while sustaining robust investment in drug development.
 

Moderator

Sarah Owermohle
Health Care Reporter, POLITICO; Co-author, POLITICO Pulse
 

Speakers

Amitabh Chandra
Professor, Public Policy and Director, Health Policy, Harvard Kennedy School of Government; Professor, Business Administration, Harvard Business School

Geoffrey Porges
Senior Managing Director, Head of Therapeutics Research, Silicon Valley Bank Leerink

Lori Reilly
Chief Operating Officer, PhRMA

Randall Rutta
CEO, National Health Council
 

Materials

Building a Better Health Care System